Found 1 Presentation For Request "986P"
986P - Response to capmatinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) and MET exon 14 skipping (METex14) mutation: Whole transcriptome analysis from phase II GEOMETRY Mono-1 study
- Jürgen Wolf (Köln, Germany)
Abstract
Background
Methods
Pts with advanced
Results
Baseline tumour biopsies from 111 of 160
Conclusions
In a whole transcriptome analysis of baseline
Clinical trial identification
NCT02414139, first posted 10 April 2015.
Editorial acknowledgement
Olga Ucar of Novartis Pharmaceuticals UK Ltd, London, UK, for providing medical writing assistance.
Legal entity responsible for the study
Novartis Pharmaceuticals Corporation.
Funding
Novartis Pharmaceuticals Corporation.
Disclosure
J. Wolf: Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, Blueprint, BMS, Boehringer Ingelheim, Daiichi Sankyo, Ignyta, Janssen, Lilly, Loxo, MSD, Novartis, Pfizer, Roche, Seattle Genetics, Takeda; Financial Interests, Personal, Invited Speaker: Bayer, Chugai; Financial Interests, Institutional, Research Grant: BMS, Janssen, Novartis, Pfizer. H.J.M. Groen: Financial Interests, Institutional, Advisory Role: Eli Lilly; Financial Interests, Institutional, Advisory Board: Novartis. D.S.W. Tan: Financial Interests, Institutional, Research Grant: ACM Biolabs, Amgen, AstraZeneca, Pfizer; Financial Interests, Personal, Advisory Role: Amgen, AstraZeneca, C4 Therapeutics, DKSH, GSK, Boehringer Ingelheim, Novartis, Merck, Pfizer, Takeda, Roche. E.B. Garon: Financial Interests, Personal, Advisory Board: Novartis, Merck, BMS, EMD Serono, Regeneron, Sanofi, Natera, Shionogi, ABL Bio, Xilio, GSK, Boehringer Ingelheim, Eisai, Gilead, Eli Lilly, Personalis; Financial Interests, Institutional, Invited Speaker: Novartis, Merck, EMD Serono, Eli Lilly, Genetech, Iovance, Neon, Mirati, AstraZeneca, BMS, ABL Bio; Non-Financial Interests, Advisory Role, Scientific Advisory Board: Lungevity. D. Demanse, A. Robeva, A. Yovine: Financial Interests, Personal, Full or part-time Employment: Novartis; Financial Interests, Personal, Stocks/Shares: Novartis. L. Fairchild, A.D. Boran: Financial Interests, Personal, Full or part-time Employment: Novartis. R. Heist: Financial Interests, Personal, Advisory Board: Daichii Sankyo, Novartis, EMD Serono; Financial Interests, Personal, Invited Speaker: Chugai Roche; Financial Interests, Personal, Other, review of cancer histories: Boehringer Ingelheim; Financial Interests, Personal, Advisory Board, consulting honoraria: AbbVie; Financial Interests, Institutional, Invited Speaker: Daichii Sankyo, Novartis, AbbVie, Roche, Incyte, Mirati, Agios, Corvus, Turning Point, Lilly, Exelixis; Non-Financial Interests, Member: IASLC, ASCO, AACR.